Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 13:09, 11 November 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL', 'StdInChI', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Cabazitaxel

Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a611009
License data	EU EMA: by INN US FDA: Cabazitaxel
Routes of administration	Intravenous
ATC code	None
Legal status
Legal status	UK: POM (Prescription only) US: WARNINGRx-only
Identifiers
IUPAC name (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracycloheptadec-13-ene-2-yl benzoate
PubChem CID	9854073
DrugBank	DB06772
ChemSpider	8029779
UNII	51F690397J
CompTox Dashboard (EPA)	DTXSID40171389
ECHA InfoCard	100.205.741
Chemical and physical data
Formula	C45H57NO14
Molar mass	835.93 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
InChI InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1 Key:BMQGVNUXMIRLCK-OAGWZNDDSA-N
(what is this?)  (verify)

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor.

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following or during docetaxel-based treatment.

Clinical trials

In a phase III trial with 755 men for the treatment of hormone-refractory prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3-4 neutropenia (81.7%) than mitoxantrone (58%).

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. http://www.cancer.gov/drugdictionary/?CdrID=534131
3. "Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review" (Press release). sanofi-aventis. 2010-06-17. Retrieved June 17, 2010.
4. "Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere".

External links

• Cabazitaxel - Official web site of manufacturer.
• Cabazitaxel Prescribing Information - Official prescribing information.
• U.S. National Library of Medicine: Drug Information Portal - Cabazitaxel

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Microtubule inhibitors
• Mitotic inhibitors
• Carbamates
• Benzoates
• Acetate esters
• Antineoplastic and immunomodulating drug stubs